{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:03Z","timestamp":1787026623721,"version":"build-2736575974"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gallbladder cancer is usually discovered as an incidental finding during or after cholecystectomy for gallstones. Most patients have advanced gallbladder cancer at diagnosis and have lost the opportunity for radical surgery, leading to dismal prognosis. Standard conversion therapy regimen is still in exploration. We reported a patient with unresectable biliary tract cancer (most likely gallbladder cancer) and multiple metastases (TxN2M1) discovered one month after laparoscopic gallstone surgery. The patient received margin-free resection after 9 cycles of immunotherapy (camrelizumab) combined with chemotherapy, followed by adjuvant immunochemotherapy. Pathological complete response was achieved and no disease recurrence occurred 5 months after surgery. Decreased neutrophil count was the only grade 3\u20134 treatment-related adverse event during the 9 cycles of conversion therapy. This case provides some reference for the conversion therapy of advanced gallbladder cancer or other biliary tract cancers.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1750556","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:31:51Z","timestamp":1783333911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful R0 resection following conversion immunochemotherapy in a patient with biliary tract cancer and multiple metastases discovered after laparoscopic gallstone surgery"],"prefix":"10.3389","volume":"17","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningjia","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Biliary Tract Diseases Institute, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Biliary Tract Diseases Institute, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Biliary Tract Diseases Institute, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shanghai Xuhui Central Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Shanghai Xuhui Central Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Imaging and Interventional Radiology, Shanghai Xuhui Central Hospital, Xuhui Hospital of Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houbao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Shanghai Xuhui District Central Hospital, Zhongshan-Xuhui Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Department of General Surgery, Zhongshan Hospital, Fudan University","place":["Shanghai, China"]},{"name":"Biliary Tract Diseases Institute, Fudan University","place":["Shanghai, China"]},{"name":"Shanghai Engineering Research Center of Biliary Tract Minimal Invasive Surgery and Materials","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jso.20527","article-title":"Gallbladder cancer","volume":"8","author":"Roa","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106234","article-title":"Current management of incidental gallbladder cancer: a review","volume":"98","author":"Feo","year":"2022","journal-title":"Int J Surg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/s2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0278","article-title":"FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis","volume":"3","author":"Tomasello","year":"2017","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00339-9","article-title":"Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial","volume":"8","author":"Chiang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: the randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112139-20250310-00118","article-title":"Expert consensus on conversion therapy of biliary tract cancer","volume":"63","year":"2025","journal-title":"Zhonghua Wai Ke Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255403","article-title":"PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer","volume":"16","author":"Zhang","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-024-02053-3","article-title":"A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin","volume":"18","author":"Araki","year":"2024","journal-title":"Clin J Gastroenterol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01383","article-title":"SWOG S1815: a phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers","volume":"43","author":"Shroff","year":"2025","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001540","article-title":"Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study","volume":"110","author":"Wang","year":"2024","journal-title":"Int J Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750556\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:31:56Z","timestamp":1783333916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1750556\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2026.1750556"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1750556","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"article-number":"1750556"}}